In response to the urgent concern plaguing the pharmaceutical industry, Eminence Business Media takes immense pride in announcing the highly anticipated 2nd Annual Pharma Impurity Conclave 2024, a symposium dedicated to solving the stubborn challenges by complying with the esteemed pharma fraternity.
The paramount objective and recurring theme for the pharmaceutical sector shall forever be to uphold the safety and efficacy of medicinal compounds. In pursuit of these noble goals and in harmonious compliance with regulatory bodies, the global standards of the pharma industry have witnessed an unprecedented surge in R&D activities, fostering unparalleled quality benchmarks. The onus now lies on pharmaceutical professionals to shoulder the noble responsibility of delivering top-notch medications, transcending the boundaries of maladies and countries of focus.
While the exhaustive evolution of medicines has led to remarkable breakthroughs, the R&D journey has also encountered numerous challenges, particularly concerning drug impurities. With the advent of various discoveries and synthesis processes, various contaminants have been observed in drug formulations, presenting an array of complex challenges and disputes. However, driven by unwavering determination, the resolute pharma industry has confronted this diversity with remarkable efficiency and precision. Nevertheless, 2018 had a new obstacle in store – NITROSAMINES, which remains the most prominent concern for the industry.
Pharma Impurity Conclave 2024 aspires to surmount the most widely discussed challenges with unwavering efficacy, offering concrete solutions through in-depth exploration of the various layers of obstacles, thereby fortifying drug impurity profiling practices by evaluating their sources and processes. Though industry professionals are already familiar with multiple mechanisms of identification and risk assessment, the missing piece of the puzzle lies in quantifying uncertainty.
From delving into practical case studies to comprehending the latest guideline updates, this meticulously curated program is designed to address the most recent and pressing challenges concerning impurity mechanisms, adopting cutting-edge and distinctive learning tools. Attendees will have the unique opportunity to learn from distinguished experts and apply their theoretical hypotheses in the stimulating Pharma Impurity Conclave 2024 setting.
Thus, a new day brings forth another captivating program, wherein the timeless challenge is met with a fresh perspective and innovative approach, promising novel insights and solutions.
Toxicologist, Risk Science Consortium & Former Toxicologist at US FDA
Executive Vice President-
R&D/Vertical Head (T-CEM & BRaIN)
Senior Vice President – Analytical R&D and Development Quality Assurance
Vice President
Associate VP
Vice President -
Analytical Solutions
Senior Vice President and Head -
Toxicology (Nonclinical Safety Assessment)
Sales Development Manager
Manager -
GC/GCMS Product Marketing
Manager - CSC
Application Manager
Senior Director, Analytical
Head - Global Toxicology
& Nonclinical Development
Principal Scientist -
Chemical Research Department
General Manager
Associate Director – Analytical R&D
115/1 NANAKRAMGUDA, FINANCIAL DISTRICT, GACHIBOWLI, HYDERABAD, TELANGANA, INDIA, 500032
This website is Powered by WebEmUp